Ivosidenib - Wikipedia
网页Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. [4] It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is …
FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma
网页On August 25, 2021, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic...
TIBSOVO® (ivosidenib tablets)
网页Treatment for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) & cholangiocarcinoma (CCA). See Full Prescribing Information & Boxed Warning.
Ivosidenib - NCI - National Cancer Institute
网页Ivosidenib works by blocking an abnormal enzyme that some cancer cells with specific changes in the IDH-1 gene make. Blocking the abnormal enzyme may make cancer cells differentiate to become more like normal cells and grow more slowly.
Tibsovo: Uses, Dosage, Side Effects, Warnings - Drugs.com
网页2018年7月20日 · Tibsovo (ivosidenib) is used to treat acute myeloid leukemia (AML), cholangiocarcinoma, and myelodysplastic syndromes in adult patients who have an isocitrate dehydrogenase-1 (IDH1) genetic mutation as detected by an FDA-approved test.
FDA Approves New Therapy for Rare Form of Blood Cancers Called ...
网页The FDA approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with an isocitrate dehydrogenase-1 mutation.
Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid …
网页2022年4月20日 · Ivosidenib — a first-in-class, oral, potent, targeted small-molecule inhibitor of mutant IDH1 — has shown clinical activity as a single agent in studies involving patients with hematologic and ...
FDA approves ivosidenib for myelodysplastic syndromes
网页On October 24, 2023, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS)...
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or ...
网页2018年6月2日 · Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1. Methods. We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1...
Ivosidenib Tablets: Uses & Side Effects - Cleveland Clinic
网页Ivosidenib works to stop cancer cells from growing to treat acute myelogenous leukemia and cholangiocarcinoma. This medication comes in a tablet form. You can take it by mouth as directed.